Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

Approvals Action
Gilead's breast cancer drug ticked

Posted 13 September 2021

Gilead's new breast cancer drug Trodelvy has been ticked by the TGA, close to seven months after the regulator accepted the therapy under its priority review pathway.

The company added the drug to its oncology pipeline when it bought Immunomedics for approximately US$21 billion (AU $29 billion), contracting Adjutor Healthcare to handle the regulatory processes locally.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Timely support for meds regulator
Threats and harassment may warrant extra TGA powers
Approvals Action
Four new therapies ticked
Plus, the disputed first generic of MSD?s diabetes drug